LGMD is a group of diseases, not a single diagnosis
The German Society for Muscular Diseases (DGM) describes LGMD as a group of nearly 30 muscular dystrophies. The shared clinical label refers mainly to proximal weakness around the pelvic and shoulder girdles, but age at onset, speed of progression, calf enlargement, contractures, cardiac disease, respiratory weakness and other features vary substantially by subtype.
A modern second opinion should aim for a molecular subtype
A historical label such as 'LGMD2' or 'limb-girdle dystrophy, type unknown' may need re-evaluation. Current assessment combines family history and inheritance pattern with clinical examination, CK, ENG/EMG where useful, muscle MRI or ultrasound and targeted molecular testing. Existing genetic data should be interpreted in the context of the phenotype rather than treating every variant as causal.
- Age at symptom onset and progression
- Pelvic- versus shoulder-girdle pattern
- Scapular winging, calf enlargement or contractures
- CK level and previous EMG findings
- Muscle MRI pattern if available
- Full genetic report including variant classification
- Family history and parental testing when relevant
Muscle biopsy is selected, not automatically repeated
Freiburg and Heidelberg neuromuscular services have access to muscle imaging, genetics and biopsy. If a high-quality previous biopsy and modern molecular result already answer the diagnostic question, repeating biopsy may add little. In unresolved cases, pathology can still help distinguish muscular dystrophy from inflammatory, metabolic or other myopathic processes and can guide additional genetic work-up.
Cardiac surveillance depends on the LGMD subtype
Some LGMD forms have clinically important cardiomyopathy or conduction/arrhythmia risk, while others have less cardiac involvement. Charité specifically includes LGMD among muscular dystrophies evaluated for cardiac involvement. Once the molecular subtype is known, the neuromuscular and cardiology teams can define whether ECG, echocardiography, Holter monitoring or cardiac MRI should be part of follow-up.
Respiratory risk also varies by gene and disease stage
Respiratory-muscle weakness can occur in selected LGMD subtypes and may become clinically relevant even before a patient loses all walking ability. Pulmonary-function testing, cough effectiveness, nocturnal symptoms and sleep-related hypoventilation should be assessed according to subtype and severity. Acute breathing deterioration requires urgent local care rather than delayed international travel.
Rehabilitation is individualized around function, not diagnosis name alone
Physiotherapy and occupational therapy aim to preserve mobility, range of motion and participation without excessive overuse. Orthoses, mobility devices and home/work adaptations can reduce falls and energy expenditure. The plan should reflect the patient's current strength pattern, contractures, pain, fatigue and respiratory status.
- Gait, transfers and stair function
- Shoulder and upper-limb function
- Contracture prevention and stretching
- Ankle-foot or other orthoses where useful
- Mobility devices for safety and longer distances
- Energy conservation and workplace adaptations
Orthopedic problems need neuromuscular context
Contractures, foot deformity, scoliosis or hip and shoulder problems can become important in some LGMD subtypes. Orthopedic procedures should be planned with the neuromuscular team because respiratory reserve, cardiac risk, postoperative immobilization and rehabilitation capacity can alter both anesthesia and expected functional benefit.
There is no universal LGMD drug or gene-therapy package
LGMD research includes gene-replacement, gene-editing and other subtype-specific strategies, but eligibility and evidence depend on the exact gene and protocol. A clinical trial is not established treatment and should not be marketed as a guaranteed gene-therapy route. A patient with an unresolved molecular diagnosis should prioritize diagnostic clarification before paying for experimental-treatment travel.
Genetic counseling matters for relatives and family planning
LGMD subtypes can be autosomal recessive or autosomal dominant and have different recurrence risks. Once a pathogenic molecular diagnosis is established, human-genetics counseling can explain testing of relatives, carrier status and reproductive options without assuming that every family member with a variant will have the same phenotype.
What to send for a German LGMD second opinion
The center can define the next diagnostic step much better when complete previous records are reviewed before travel.
- Full molecular genetic report, not only a one-line diagnosis
- Neuromuscular specialist reports and family history
- CK and other laboratory results
- ENG/EMG reports
- Muscle MRI or ultrasound and original images when available
- Muscle-biopsy pathology report and slides/blocks if the center requests them
- ECG, echocardiography, Holter or cardiac MRI if previously performed
- Pulmonary-function and sleep-study results
- Physiotherapy, orthotic and mobility records
- A specific question: confirm subtype, unresolved genetics, cardiac/respiratory surveillance, rehabilitation, orthopedic review or clinical-trial eligibility
Official sources
Sources last checked 2026-09-01. Clinical pathways, eligibility and hospital procedures can change; confirm current requirements directly with the treating center.
- LGMD (Gliedergürteldystrophie) — German Society for Muscular Diseases (DGM) ↗
- Freiburg Center for Neuromuscular Diseases in Childhood — University Medical Center Freiburg ↗
- Freiburg Neuromuscular Clinic — University Medical Center Freiburg ↗
- Heidelberg neuromuscular outpatient clinic — Heidelberg University Hospital ↗
- Charité neuromuscular diseases — Charité – Universitätsmedizin Berlin ↗
- Charité cardiology – muscular dystrophies including LGMD — Charité – Universitätsmedizin Berlin ↗